X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs TORRENT PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA TORRENT PHARMA ABBOTT INDIA/
TORRENT PHARMA
 
P/E (TTM) x 41.1 45.5 90.4% View Chart
P/BV x 10.6 6.4 164.6% View Chart
Dividend Yield % 0.7 0.8 81.8%  

Financials

 ABBOTT INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
TORRENT PHARMA
Mar-18
ABBOTT INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6,1101,550 394.2%   
Low Rs3,9961,144 349.5%   
Sales per share (Unadj.) Rs1,552.2354.7 437.6%  
Earnings per share (Unadj.) Rs188.840.1 471.1%  
Cash flow per share (Unadj.) Rs196.464.2 305.9%  
Dividends per share (Unadj.) Rs55.0014.00 392.9%  
Dividend yield (eoy) %1.11.0 104.7%  
Book value per share (Unadj.) Rs796.6273.1 291.6%  
Shares outstanding (eoy) m21.25169.22 12.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.8 85.7%   
Avg P/E ratio x26.833.6 79.6%  
P/CF ratio (eoy) x25.721.0 122.7%  
Price / Book Value ratio x6.34.9 128.7%  
Dividend payout %29.134.9 83.4%   
Avg Mkt Cap Rs m107,376227,897 47.1%   
No. of employees `0003.314.7 22.6%   
Total wages/salary Rs m3,93711,353 34.7%   
Avg. sales/employee Rs Th9,929.34,083.0 243.2%   
Avg. wages/employee Rs Th1,185.1772.3 153.5%   
Avg. net profit/employee Rs Th1,207.7461.3 261.8%   
INCOME DATA
Net Sales Rs m32,98560,021 55.0%  
Other income Rs m1,1702,988 39.1%   
Total revenues Rs m34,15563,009 54.2%   
Gross profit Rs m5,24513,493 38.9%  
Depreciation Rs m1624,086 4.0%   
Interest Rs m383,085 1.2%   
Profit before tax Rs m6,2159,310 66.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2032,529 87.1%   
Profit after tax Rs m4,0126,781 59.2%  
Gross profit margin %15.922.5 70.7%  
Effective tax rate %35.427.2 130.5%   
Net profit margin %12.211.3 107.7%  
BALANCE SHEET DATA
Current assets Rs m22,65552,623 43.1%   
Current liabilities Rs m6,68152,022 12.8%   
Net working cap to sales %48.41.0 4,832.4%  
Current ratio x3.41.0 335.2%  
Inventory Days Days65120 54.2%  
Debtors Days Days2976 38.2%  
Net fixed assets Rs m83585,016 1.0%   
Share capital Rs m213846 25.1%   
"Free" reserves Rs m16,71545,376 36.8%   
Net worth Rs m16,92846,222 36.6%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m24,162142,432 17.0%  
Interest coverage x163.74.0 4,073.9%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.40.4 324.0%   
Return on assets %16.86.9 242.0%  
Return on equity %23.714.7 161.5%  
Return on capital %36.914.2 260.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36914,580 2.5%   
Fx outflow Rs m3,8073,600 105.7%   
Net fx Rs m-3,43810,980 -31.3%   
CASH FLOW
From Operations Rs m1,5278,942 17.1%  
From Investments Rs m-2,148-47,070 4.6%  
From Financial Activity Rs m-1,02434,174 -3.0%  
Net Cashflow Rs m-1,646-3,655 45.0%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 7.0 112.5%  
FIIs % 0.1 12.6 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.8 194.3%  
Shareholders   18,270 26,511 68.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  BIOCON LTD  J.B.CHEMICALS  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 19, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS